A Life Changer in Cancer Diagnostics

Cancer Screening and Liquid Biopsy 2.0

Learn More

Early screening

We harvest the potential of two fundamental indicators of cancer:

tumor metabolism and extracellular vesicles released by cancer cells

Learn More


We provide high quality services to support fundamental and streamlined EV research
Learn More


Meet the Exosomics Team

Learn more

our Mission

Our mission is to develop and commercialize a new generation of proprietary assays for cancer screening and liquid biopsy, based on analysis of tumor derived exosomes and their cargo.

our vision

A world in which a simple blood draw will be sufficient for early cancer screening and liquid biopsy, enabling physicians to detect early cancers and to optimize patients’ treatment.

our values

Caring about Human Health with Honesty – Adopting High Standard Solutions – Making a Difference Through Innovative Thinking – Teamwork – Partnership and Trust with Academy and Industry.

Exosomics’ strengths


We provide accurate cancer screening  and liquid biopsy from a routine blood draw, truly suitable for early cancer detection and for active patients’ management and monitoring.


We tackle innovative biological principles and evolving science and technologies to design and validate highly accurate diagnostic tests.



Our approach is based on the detection of fundamental drivers of cancer and cancer hallmarks shuttled by tumor exosomes as early sentinels of tumor occurrence.


Our tests are simple, reliable, and cost-effective. We offer scalable and user friendly test formats and provide them as open platform solutions.


Current investors are: Lonza, BioBalt Holding, BioFund, FinBiotech, and Black Swan Trade